Master Adaptive News Today

Number of years in the consortium: 8 years Of note, all 4 items below apply to our work in the ACE consortium since 2013. In addition to our original proposal (which transformed our whole medical education program), our renewal was focused on going deeper in three elements: (1) competency-based medical education, (2) health systems science, and (3) advising/coaching across the undergraduate to graduate medical education continuum. In addition, we have worked separately on a grant provided by t...

Share this article Share this article SCHAUMBURG, Ill., Feb. 12, 2021 /PRNewswire/ -- Sagent Pharmaceuticals, a Nichi-Iko Group Company, announced today that Camostat mesilate (Camostat), is one of four therapies being added to the existing ACTIV-2 Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID), which was launched by the National Institutes of Health (NIH) and the AIDS Clinical Trials Group (ACTG) in May 2020. ACTG was tasked with leading a Master Adaptive pr...